Elisabetta Walters1, Marieke Magrieta van der Zalm, Megan Palmer, Corné Bosch, Anne-Marie Demers, Heather Draper, Pierre Goussard, Hendrik Simon Schaaf, Sven Olaf Friedrich, Andrew Whitelaw, Robin Warren, Robert P Gie, Anneke C Hesseling. 1. From the *Desmond Tutu TB Centre, Department of Paediatrics and Child Health, †DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, MRC Centre for Tuberculosis Research, Division of Medical Physiology, Faculty of Medicine and Health Sciences, ‡Department of Medical Microbiology and National Health Laboratory Service, §DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, US/SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, and ¶Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Abstract
BACKGROUND: Tuberculosis (TB) continues to result in high morbidity and mortality in children from resource-limited settings. Diagnostic challenges, including resource-intense sputum collection methods and insensitive diagnostic tests, contribute to diagnostic delay and poor outcomes in children. We evaluated the diagnostic utility of stool Xpert MTB/RIF (Xpert) compared with bacteriologic confirmation (combination of Xpert and culture of respiratory samples). METHODS: In a hospital-based study in Cape Town, South Africa, we enrolled children younger than 13 years of age with suspected pulmonary TB from April 2012 to August 2015. Standard clinical investigations included tuberculin skin test, chest radiograph and HIV testing. Respiratory samples for smear microscopy, Xpert and liquid culture included gastric aspirates, induced sputum, nasopharyngeal aspirates and expectorated sputum. One stool sample per child was collected and tested using Xpert. RESULTS: Of 379 children enrolled (median age, 15.9 months, 13.7% HIV infected), 73 (19.3%) had bacteriologically confirmed TB. The sensitivity and specificity of stool Xpert versus overall bacteriologic confirmation were 31.9% [95% confidence interval (CI): 21.84%-44.50%] and 99.7% (95% CI: 98.2%-100%), respectively. A total of 23/51 (45.1%) children with bacteriologically confirmed TB with severe disease were stool Xpert positive. Cavities on chest radiograph were associated with Xpert stool positivity regardless of age and other relevant factors [odds ratios (OR) 7.05; 95% CI: 2.16-22.98; P = 0.001]. CONCLUSIONS: Stool Xpert can rapidly confirm TB in children who present with radiologic findings suggestive of severe TB. In resource-limited settings where children frequently present with advanced disease, Xpert on stool samples could improve access to rapid diagnostic confirmation and appropriate treatment.
BACKGROUND:Tuberculosis (TB) continues to result in high morbidity and mortality in children from resource-limited settings. Diagnostic challenges, including resource-intense sputum collection methods and insensitive diagnostic tests, contribute to diagnostic delay and poor outcomes in children. We evaluated the diagnostic utility of stool Xpert MTB/RIF (Xpert) compared with bacteriologic confirmation (combination of Xpert and culture of respiratory samples). METHODS: In a hospital-based study in Cape Town, South Africa, we enrolled children younger than 13 years of age with suspected pulmonary TB from April 2012 to August 2015. Standard clinical investigations included tuberculin skin test, chest radiograph and HIV testing. Respiratory samples for smear microscopy, Xpert and liquid culture included gastric aspirates, induced sputum, nasopharyngeal aspirates and expectorated sputum. One stool sample per child was collected and tested using Xpert. RESULTS: Of 379 children enrolled (median age, 15.9 months, 13.7% HIV infected), 73 (19.3%) had bacteriologically confirmed TB. The sensitivity and specificity of stool Xpert versus overall bacteriologic confirmation were 31.9% [95% confidence interval (CI): 21.84%-44.50%] and 99.7% (95% CI: 98.2%-100%), respectively. A total of 23/51 (45.1%) children with bacteriologically confirmed TB with severe disease were stool Xpert positive. Cavities on chest radiograph were associated with Xpert stool positivity regardless of age and other relevant factors [odds ratios (OR) 7.05; 95% CI: 2.16-22.98; P = 0.001]. CONCLUSIONS: Stool Xpert can rapidly confirm TB in children who present with radiologic findings suggestive of severe TB. In resource-limited settings where children frequently present with advanced disease, Xpert on stool samples could improve access to rapid diagnostic confirmation and appropriate treatment.
Authors: James A Seddon; Peter Godfrey-Faussett; Anneke C Hesseling; Robert P Gie; Nulda Beyers; H Simon Schaaf Journal: Lancet Infect Dis Date: 2012-02-27 Impact factor: 25.071
Authors: Chifumbe Chintu; Victor Mudenda; Sebastian Lucas; Andrew Nunn; Kennedy Lishimpi; Daniel Maswahu; Francis Kasolo; Peter Mwaba; Ganapati Bhat; Hiroshi Terunuma; Alimuddin Zumla Journal: Lancet Date: 2002-09-28 Impact factor: 79.321
Authors: Hilary Wolf; Melissa Mendez; Robert H Gilman; Patricia Sheen; Giselle Soto; Angie K Velarde; Mirko Zimic; A Roderick Escombe; Sonia Montenegro; Richard A Oberhelman; Carlton A Evans Journal: Am J Trop Med Hyg Date: 2008-12 Impact factor: 2.345
Authors: Rewa K Choudhary; Kristin M Wall; Irene Njuguna; Patricia B Pavlinac; Sylvia M LaCourse; Vincent Otieno; John Gatimu; Joshua Stern; Elizabeth Maleche-Obimbo; Dalton Wamalwa; Grace John-Stewart; Lisa M Cranmer Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Elisabetta Walters; Anne-Marie Demers; Marieke M van der Zalm; Andrew Whitelaw; Megan Palmer; Corné Bosch; Heather R Draper; Robert P Gie; Anneke C Hesseling Journal: J Clin Microbiol Date: 2018-04-25 Impact factor: 5.948
Authors: Elisabetta Walters; Marieke M van der Zalm; Anne-Marie Demers; Andrew Whitelaw; Megan Palmer; Corné Bosch; Heather R Draper; H Simon Schaaf; Pierre Goussard; Carl J Lombard; Robert P Gie; Anneke C Hesseling Journal: Pediatr Infect Dis J Date: 2019-06 Impact factor: 2.129
Authors: C L Jasumback; Q Dlamini; J Kahari; G Maphalala; M G Dlamini; G S Dube; A DiNardo; H L Kirchner; A Mandalakas; A W Kay Journal: Public Health Action Date: 2021-06-21
Authors: Andrew R DiNardo; Alexander W Kay; Gugu Maphalala; Nadine M Harris; Celia Fung; Godwin Mtetwa; Pilar Ustero; Sindisiwe Dlamini; Ngan Ha; Edward A Graviss; Rojelio Mejia; Anna M Mandalakas Journal: Am J Trop Med Hyg Date: 2018-04-19 Impact factor: 2.345
Authors: Sylvia M LaCourse; Patricia B Pavlinac; Lisa M Cranmer; Irene N Njuguna; Cyrus Mugo; John Gatimu; Joshua Stern; Judd L Walson; Elizabeth Maleche-Obimbo; Julius Oyugi; Dalton Wamalwa; Grace John-Stewart Journal: AIDS Date: 2018-01-02 Impact factor: 4.177
Authors: Alexander W Kay; Lucia González Fernández; Yemisi Takwoingi; Michael Eisenhut; Anne K Detjen; Karen R Steingart; Anna M Mandalakas Journal: Cochrane Database Syst Rev Date: 2020-08-27